Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycobacterium Infections, Nontuberculous | 26 | 2023 | 334 | 6.880 |
Why?
|
Mycobacterium tuberculosis | 20 | 2023 | 304 | 5.690 |
Why?
|
Tuberculosis | 16 | 2023 | 266 | 5.560 |
Why?
|
Nontuberculous Mycobacteria | 18 | 2023 | 205 | 4.150 |
Why?
|
Lung Diseases | 14 | 2023 | 764 | 3.760 |
Why?
|
Tuberculosis, Multidrug-Resistant | 11 | 2021 | 45 | 3.530 |
Why?
|
Tuberculosis, Pulmonary | 14 | 2020 | 127 | 3.190 |
Why?
|
alpha 1-Antitrypsin | 5 | 2022 | 123 | 2.800 |
Why?
|
Interleukins | 9 | 2019 | 246 | 2.480 |
Why?
|
Mycobacterium avium Complex | 8 | 2023 | 96 | 2.400 |
Why?
|
alpha 1-Antitrypsin Deficiency | 6 | 2023 | 89 | 2.390 |
Why?
|
Antitubercular Agents | 12 | 2020 | 167 | 2.280 |
Why?
|
Macrophages, Alveolar | 9 | 2020 | 364 | 2.260 |
Why?
|
Mycobacterium avium-intracellulare Infection | 7 | 2023 | 63 | 2.140 |
Why?
|
Respiratory Tract Infections | 7 | 2019 | 335 | 1.940 |
Why?
|
Macrophages | 18 | 2022 | 1334 | 1.880 |
Why?
|
Smoking | 8 | 2020 | 1556 | 1.320 |
Why?
|
Glucocorticoids | 3 | 2021 | 554 | 1.310 |
Why?
|
Lung | 18 | 2023 | 3830 | 1.280 |
Why?
|
Interferon-gamma | 12 | 2018 | 747 | 1.250 |
Why?
|
Disease Susceptibility | 6 | 2018 | 343 | 1.250 |
Why?
|
Humans | 129 | 2023 | 122796 | 1.200 |
Why?
|
Bronchiectasis | 4 | 2021 | 102 | 1.190 |
Why?
|
NF-kappa B | 9 | 2022 | 676 | 1.150 |
Why?
|
Interleukin-8 | 6 | 2022 | 256 | 1.070 |
Why?
|
Epithelial Cells | 6 | 2020 | 995 | 1.030 |
Why?
|
Antimicrobial Cationic Peptides | 3 | 2020 | 77 | 0.950 |
Why?
|
Macrophage Activation | 2 | 2021 | 169 | 0.900 |
Why?
|
Phospholipids | 4 | 2020 | 211 | 0.890 |
Why?
|
Nicotine | 3 | 2023 | 276 | 0.870 |
Why?
|
Mycobacterium | 5 | 2023 | 105 | 0.870 |
Why?
|
Solitary Pulmonary Nodule | 2 | 2021 | 27 | 0.860 |
Why?
|
Edema | 2 | 2017 | 130 | 0.860 |
Why?
|
Cigarette Smoking | 1 | 2023 | 87 | 0.850 |
Why?
|
Latent Tuberculosis | 2 | 2015 | 63 | 0.850 |
Why?
|
Critical Care | 2 | 2019 | 563 | 0.850 |
Why?
|
Enoxaparin | 1 | 2022 | 52 | 0.820 |
Why?
|
Respiratory Mucosa | 3 | 2020 | 263 | 0.810 |
Why?
|
Receptors, Glucocorticoid | 1 | 2022 | 136 | 0.810 |
Why?
|
Thinness | 2 | 2013 | 94 | 0.790 |
Why?
|
Angioedema | 1 | 2021 | 17 | 0.780 |
Why?
|
Tomography, X-Ray Computed | 9 | 2021 | 2500 | 0.780 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 3 | 2009 | 6 | 0.770 |
Why?
|
Sjogren's Syndrome | 1 | 2021 | 40 | 0.770 |
Why?
|
Apoptosis | 6 | 2020 | 2532 | 0.770 |
Why?
|
Angioedemas, Hereditary | 1 | 2020 | 7 | 0.770 |
Why?
|
Lung Neoplasms | 6 | 2021 | 2216 | 0.760 |
Why?
|
Mycobacterium Infections | 5 | 2023 | 65 | 0.750 |
Why?
|
Nitric Oxide | 6 | 2017 | 884 | 0.740 |
Why?
|
Immunoassay | 1 | 2020 | 101 | 0.720 |
Why?
|
Immune Evasion | 1 | 2020 | 48 | 0.720 |
Why?
|
Funnel Chest | 3 | 2017 | 23 | 0.720 |
Why?
|
Membrane Lipids | 1 | 2020 | 88 | 0.700 |
Why?
|
Lipopolysaccharides | 5 | 2022 | 875 | 0.690 |
Why?
|
Disease Models, Animal | 5 | 2023 | 3799 | 0.670 |
Why?
|
Lung Diseases, Fungal | 1 | 2018 | 14 | 0.670 |
Why?
|
Parasitic Diseases | 1 | 2018 | 11 | 0.660 |
Why?
|
Smoke | 3 | 2020 | 146 | 0.660 |
Why?
|
Oximetry | 2 | 2013 | 96 | 0.660 |
Why?
|
Microbial Viability | 3 | 2020 | 82 | 0.650 |
Why?
|
Pneumonia, Mycoplasma | 3 | 2011 | 33 | 0.640 |
Why?
|
Granuloma | 3 | 2021 | 93 | 0.630 |
Why?
|
Fluoroquinolones | 3 | 2018 | 43 | 0.620 |
Why?
|
Collateral Circulation | 1 | 2017 | 20 | 0.600 |
Why?
|
Anti-Bacterial Agents | 6 | 2016 | 1562 | 0.600 |
Why?
|
T-Lymphocytes, Regulatory | 5 | 2023 | 367 | 0.600 |
Why?
|
Scoliosis | 3 | 2017 | 186 | 0.600 |
Why?
|
Virulence Factors | 1 | 2018 | 143 | 0.590 |
Why?
|
Lymphadenopathy | 1 | 2016 | 8 | 0.570 |
Why?
|
Vena Cava, Inferior | 1 | 2017 | 56 | 0.570 |
Why?
|
Tularemia | 1 | 2016 | 16 | 0.570 |
Why?
|
Acute Pain | 1 | 2017 | 32 | 0.570 |
Why?
|
Francisella tularensis | 1 | 2016 | 18 | 0.570 |
Why?
|
Ciprofloxacin | 1 | 2016 | 24 | 0.570 |
Why?
|
Bacterial Infections | 1 | 2018 | 234 | 0.570 |
Why?
|
Vascular Malformations | 1 | 2017 | 47 | 0.570 |
Why?
|
Thorax | 1 | 2016 | 49 | 0.560 |
Why?
|
Hemangioma, Capillary | 2 | 2006 | 13 | 0.560 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2016 | 27 | 0.560 |
Why?
|
Curcumin | 1 | 2016 | 36 | 0.550 |
Why?
|
Low Back Pain | 1 | 2017 | 103 | 0.530 |
Why?
|
Venous Thrombosis | 1 | 2017 | 148 | 0.520 |
Why?
|
Biofilms | 6 | 2018 | 236 | 0.510 |
Why?
|
Animals | 31 | 2023 | 34133 | 0.510 |
Why?
|
Models, Biological | 2 | 2020 | 1756 | 0.500 |
Why?
|
Cyclonic Storms | 1 | 2015 | 35 | 0.490 |
Why?
|
Cerebral Hemorrhage | 1 | 2015 | 101 | 0.490 |
Why?
|
Mice | 20 | 2023 | 15888 | 0.490 |
Why?
|
Autophagy | 4 | 2021 | 321 | 0.490 |
Why?
|
Mycobacterium abscessus | 3 | 2021 | 97 | 0.480 |
Why?
|
Octreotide | 1 | 2013 | 27 | 0.480 |
Why?
|
Somatostatin | 1 | 2013 | 54 | 0.480 |
Why?
|
Mycobacterium avium | 5 | 2023 | 23 | 0.480 |
Why?
|
Disasters | 1 | 2015 | 90 | 0.470 |
Why?
|
Biomimetic Materials | 1 | 2014 | 69 | 0.470 |
Why?
|
Environmental Exposure | 2 | 2015 | 427 | 0.460 |
Why?
|
Interleukin-4 | 3 | 2009 | 230 | 0.460 |
Why?
|
Amikacin | 2 | 2018 | 21 | 0.450 |
Why?
|
Cell Line | 9 | 2017 | 2785 | 0.450 |
Why?
|
Risk Factors | 12 | 2021 | 9381 | 0.450 |
Why?
|
Chemokine CXCL10 | 2 | 2010 | 40 | 0.450 |
Why?
|
Transforming Growth Factor beta | 2 | 2013 | 468 | 0.430 |
Why?
|
Diagnosis, Differential | 6 | 2021 | 1423 | 0.420 |
Why?
|
Mycoplasma pneumoniae | 2 | 2011 | 33 | 0.420 |
Why?
|
Interleukin-18 | 4 | 2011 | 229 | 0.420 |
Why?
|
Monocytes | 3 | 2011 | 523 | 0.420 |
Why?
|
Nitric Oxide Synthase | 2 | 2003 | 227 | 0.420 |
Why?
|
Tumor Necrosis Factor-alpha | 9 | 2015 | 1181 | 0.410 |
Why?
|
Chemokine CXCL9 | 1 | 2010 | 22 | 0.390 |
Why?
|
Serine Endopeptidases | 2 | 2022 | 104 | 0.390 |
Why?
|
Cell Membrane | 2 | 2020 | 741 | 0.380 |
Why?
|
Genetic Predisposition to Disease | 4 | 2017 | 2359 | 0.380 |
Why?
|
Respiratory System | 1 | 2011 | 144 | 0.380 |
Why?
|
Male | 38 | 2021 | 59639 | 0.370 |
Why?
|
Middle Aged | 26 | 2021 | 28563 | 0.360 |
Why?
|
Bronchi | 2 | 2008 | 253 | 0.350 |
Why?
|
Streptomycin | 1 | 2009 | 15 | 0.350 |
Why?
|
Nitric Oxide Synthase Type II | 5 | 2017 | 171 | 0.330 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.330 |
Why?
|
Wound Healing | 1 | 2010 | 279 | 0.330 |
Why?
|
Virulence | 4 | 2020 | 254 | 0.330 |
Why?
|
Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.330 |
Why?
|
Otitis Media | 1 | 2010 | 149 | 0.320 |
Why?
|
Anti-Inflammatory Agents | 2 | 2022 | 469 | 0.320 |
Why?
|
Up-Regulation | 3 | 2011 | 891 | 0.310 |
Why?
|
Meningitis, Bacterial | 1 | 2008 | 50 | 0.310 |
Why?
|
Dendritic Cells | 3 | 2021 | 445 | 0.310 |
Why?
|
Cytokines | 5 | 2023 | 1928 | 0.310 |
Why?
|
Public Health | 1 | 2012 | 480 | 0.310 |
Why?
|
Female | 37 | 2023 | 63629 | 0.300 |
Why?
|
Gene Expression | 4 | 2018 | 1506 | 0.300 |
Why?
|
Comorbidity | 6 | 2021 | 1600 | 0.300 |
Why?
|
Radiography, Thoracic | 1 | 2008 | 168 | 0.300 |
Why?
|
Prevalence | 7 | 2022 | 2442 | 0.290 |
Why?
|
Mycobacteriaceae | 1 | 2007 | 21 | 0.290 |
Why?
|
Serine Proteinase Inhibitors | 2 | 2022 | 37 | 0.290 |
Why?
|
Cells, Cultured | 8 | 2019 | 4162 | 0.290 |
Why?
|
Brain Neoplasms | 1 | 2015 | 1016 | 0.290 |
Why?
|
Guinea Pigs | 3 | 2020 | 152 | 0.290 |
Why?
|
Angiomatosis | 1 | 2006 | 4 | 0.290 |
Why?
|
Soil Microbiology | 2 | 2020 | 183 | 0.290 |
Why?
|
Patient Selection | 1 | 2010 | 717 | 0.290 |
Why?
|
Adipokines | 2 | 2019 | 46 | 0.280 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 1213 | 0.280 |
Why?
|
Hawaii | 6 | 2023 | 37 | 0.280 |
Why?
|
Immunohistochemistry | 6 | 2011 | 1727 | 0.280 |
Why?
|
Diagnostic Errors | 2 | 2020 | 171 | 0.280 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2021 | 66 | 0.280 |
Why?
|
Dexamethasone | 1 | 2008 | 323 | 0.280 |
Why?
|
Immunity, Innate | 3 | 2018 | 762 | 0.270 |
Why?
|
Promoter Regions, Genetic | 3 | 2009 | 1188 | 0.270 |
Why?
|
Chronic Disease | 3 | 2018 | 1645 | 0.270 |
Why?
|
Logistic Models | 4 | 2021 | 1995 | 0.270 |
Why?
|
Body Mass Index | 3 | 2021 | 2144 | 0.270 |
Why?
|
Aged | 18 | 2021 | 20495 | 0.260 |
Why?
|
Phosphoproteins | 2 | 2009 | 332 | 0.260 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 278 | 0.260 |
Why?
|
Sodium Chloride | 1 | 2006 | 154 | 0.260 |
Why?
|
Pulmonary Emphysema | 1 | 2008 | 342 | 0.250 |
Why?
|
Cathelicidins | 3 | 2020 | 39 | 0.250 |
Why?
|
Bronchiolitis Obliterans | 1 | 2004 | 69 | 0.250 |
Why?
|
Pulmonary Ventilation | 1 | 2004 | 72 | 0.250 |
Why?
|
Methylobacterium | 1 | 2023 | 4 | 0.240 |
Why?
|
Treatment Outcome | 9 | 2018 | 9692 | 0.240 |
Why?
|
Nails | 1 | 2003 | 10 | 0.230 |
Why?
|
Bone Marrow Transplantation | 1 | 2004 | 253 | 0.230 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 839 | 0.230 |
Why?
|
Cosmetics | 1 | 2003 | 7 | 0.230 |
Why?
|
Risk Assessment | 5 | 2021 | 3213 | 0.230 |
Why?
|
Adaptive Immunity | 2 | 2015 | 165 | 0.230 |
Why?
|
Pneumonia, Bacterial | 2 | 2021 | 113 | 0.230 |
Why?
|
Lipids | 2 | 2019 | 614 | 0.230 |
Why?
|
Molecular Epidemiology | 1 | 2023 | 71 | 0.230 |
Why?
|
Th1 Cells | 1 | 2004 | 138 | 0.230 |
Why?
|
Plague | 1 | 2003 | 42 | 0.230 |
Why?
|
Angiopoietins | 1 | 2022 | 14 | 0.220 |
Why?
|
Drinking Water | 3 | 2020 | 69 | 0.220 |
Why?
|
Wounds and Injuries | 1 | 2010 | 813 | 0.220 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2006 | 302 | 0.220 |
Why?
|
Th2 Cells | 1 | 2004 | 170 | 0.220 |
Why?
|
Pancreatic Elastase | 1 | 2022 | 74 | 0.220 |
Why?
|
Case-Control Studies | 5 | 2014 | 3296 | 0.220 |
Why?
|
Antigens, Bacterial | 1 | 2003 | 120 | 0.220 |
Why?
|
Graft vs Host Disease | 1 | 2004 | 219 | 0.220 |
Why?
|
Soil | 2 | 2022 | 181 | 0.220 |
Why?
|
Fibrillins | 2 | 2013 | 8 | 0.210 |
Why?
|
Transcription Factor RelA | 2 | 2019 | 82 | 0.210 |
Why?
|
Species Specificity | 2 | 2020 | 578 | 0.210 |
Why?
|
Autophagosomes | 2 | 2021 | 21 | 0.210 |
Why?
|
Heparin | 1 | 2023 | 240 | 0.210 |
Why?
|
Gene Expression Regulation | 3 | 2008 | 2491 | 0.210 |
Why?
|
Chest Pain | 2 | 2021 | 94 | 0.200 |
Why?
|
Tyrosine | 1 | 2002 | 267 | 0.200 |
Why?
|
Adult | 20 | 2023 | 32385 | 0.200 |
Why?
|
Leisure Activities | 1 | 2021 | 28 | 0.200 |
Why?
|
Phagosomes | 2 | 2019 | 44 | 0.200 |
Why?
|
Breast Density | 1 | 2020 | 3 | 0.190 |
Why?
|
Hemoptysis | 1 | 2021 | 32 | 0.190 |
Why?
|
Microfilament Proteins | 2 | 2013 | 135 | 0.190 |
Why?
|
Virus Internalization | 1 | 2020 | 42 | 0.190 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2020 | 8 | 0.190 |
Why?
|
Bronchoalveolar Lavage Fluid | 6 | 2010 | 633 | 0.190 |
Why?
|
Extracellular Traps | 1 | 2020 | 40 | 0.190 |
Why?
|
Leukocyte Elastase | 1 | 2020 | 84 | 0.190 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2021 | 84 | 0.190 |
Why?
|
Prognosis | 5 | 2020 | 3563 | 0.190 |
Why?
|
Bias | 1 | 2021 | 207 | 0.190 |
Why?
|
Antithrombins | 1 | 2020 | 57 | 0.190 |
Why?
|
Radiologists | 1 | 2020 | 39 | 0.190 |
Why?
|
Chromatography, Thin Layer | 1 | 2020 | 23 | 0.190 |
Why?
|
Propensity Score | 1 | 2021 | 253 | 0.190 |
Why?
|
THP-1 Cells | 1 | 2020 | 24 | 0.190 |
Why?
|
Radiation Tolerance | 1 | 2021 | 98 | 0.190 |
Why?
|
Tobacco Smoke Pollution | 2 | 2015 | 235 | 0.180 |
Why?
|
Leptin | 3 | 2019 | 233 | 0.180 |
Why?
|
Mammography | 1 | 2020 | 127 | 0.180 |
Why?
|
Phylogeny | 3 | 2020 | 830 | 0.180 |
Why?
|
Observer Variation | 1 | 2020 | 314 | 0.180 |
Why?
|
HEK293 Cells | 1 | 2022 | 651 | 0.180 |
Why?
|
Protein Subunits | 3 | 2017 | 215 | 0.180 |
Why?
|
Postmenopause | 2 | 2013 | 307 | 0.180 |
Why?
|
Dyspnea | 1 | 2021 | 214 | 0.170 |
Why?
|
Adipose Tissue, White | 1 | 2019 | 37 | 0.170 |
Why?
|
Pulmonary Surfactants | 2 | 2011 | 104 | 0.170 |
Why?
|
Vitamin A | 1 | 2019 | 55 | 0.170 |
Why?
|
Lymph Nodes | 2 | 2015 | 466 | 0.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 1003 | 0.170 |
Why?
|
Interleukin-12 | 3 | 2011 | 111 | 0.170 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 159 | 0.170 |
Why?
|
Macrolides | 1 | 2019 | 66 | 0.170 |
Why?
|
Retrospective Studies | 7 | 2021 | 13433 | 0.170 |
Why?
|
Pulmonary Embolism | 2 | 2014 | 190 | 0.170 |
Why?
|
Biota | 1 | 2018 | 37 | 0.170 |
Why?
|
Shock, Septic | 1 | 2021 | 213 | 0.170 |
Why?
|
Leishmania infantum | 1 | 2018 | 4 | 0.170 |
Why?
|
Leishmaniasis, Visceral | 1 | 2018 | 5 | 0.170 |
Why?
|
DNA-Binding Proteins | 3 | 2016 | 1384 | 0.160 |
Why?
|
Mice, Inbred C57BL | 6 | 2021 | 5020 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2015 | 715 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2012 | 306 | 0.160 |
Why?
|
Emphysema | 1 | 2019 | 129 | 0.160 |
Why?
|
Protective Factors | 1 | 2018 | 96 | 0.160 |
Why?
|
Fomites | 1 | 2017 | 8 | 0.160 |
Why?
|
Enzyme Activation | 4 | 2017 | 864 | 0.160 |
Why?
|
Nicotinic Antagonists | 1 | 2017 | 20 | 0.160 |
Why?
|
Adipocytes | 1 | 2019 | 201 | 0.160 |
Why?
|
Inflammation | 5 | 2019 | 2598 | 0.150 |
Why?
|
Antioxidants | 3 | 2008 | 581 | 0.150 |
Why?
|
Interleukin-10 | 4 | 2011 | 314 | 0.150 |
Why?
|
Mitral Valve Prolapse | 1 | 2017 | 8 | 0.150 |
Why?
|
Cohort Studies | 6 | 2021 | 5294 | 0.150 |
Why?
|
Wheelchairs | 1 | 2017 | 16 | 0.150 |
Why?
|
Phenotype | 4 | 2021 | 3070 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2015 | 1003 | 0.150 |
Why?
|
Osmotic Pressure | 1 | 2017 | 33 | 0.150 |
Why?
|
Computer Simulation | 1 | 2021 | 945 | 0.150 |
Why?
|
Acute Lung Injury | 1 | 2020 | 313 | 0.150 |
Why?
|
eIF-2 Kinase | 1 | 2017 | 31 | 0.150 |
Why?
|
Interferon Regulatory Factor-1 | 2 | 2009 | 15 | 0.150 |
Why?
|
Interleukin-1beta | 2 | 2009 | 383 | 0.150 |
Why?
|
Immunotherapy | 1 | 2021 | 504 | 0.150 |
Why?
|
Mice, Transgenic | 3 | 2019 | 2079 | 0.150 |
Why?
|
Hypoxia | 2 | 2021 | 1003 | 0.150 |
Why?
|
Blotting, Western | 2 | 2010 | 1225 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2010 | 2221 | 0.140 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 1245 | 0.140 |
Why?
|
Mobility Limitation | 1 | 2017 | 66 | 0.140 |
Why?
|
Postoperative Care | 1 | 2018 | 245 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 673 | 0.140 |
Why?
|
Cancer Survivors | 1 | 2021 | 225 | 0.140 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 364 | 0.140 |
Why?
|
Serologic Tests | 1 | 2016 | 56 | 0.140 |
Why?
|
RNA, Messenger | 4 | 2017 | 2720 | 0.140 |
Why?
|
Age Factors | 2 | 2021 | 3114 | 0.140 |
Why?
|
Protective Agents | 1 | 2016 | 42 | 0.140 |
Why?
|
Household Articles | 1 | 2016 | 23 | 0.140 |
Why?
|
Regression Analysis | 3 | 2015 | 1018 | 0.140 |
Why?
|
Testis | 2 | 2009 | 145 | 0.140 |
Why?
|
Treatment Failure | 2 | 2018 | 348 | 0.140 |
Why?
|
Referral and Consultation | 1 | 2021 | 669 | 0.140 |
Why?
|
Models, Immunological | 1 | 2016 | 100 | 0.140 |
Why?
|
Sputum | 3 | 2016 | 293 | 0.140 |
Why?
|
Aged, 80 and over | 7 | 2021 | 6845 | 0.140 |
Why?
|
Head and Neck Neoplasms | 1 | 2021 | 475 | 0.140 |
Why?
|
Paramyxoviridae Infections | 2 | 2007 | 11 | 0.140 |
Why?
|
Asthma | 4 | 2008 | 2130 | 0.140 |
Why?
|
Escherichia coli | 1 | 2020 | 767 | 0.140 |
Why?
|
Metapneumovirus | 2 | 2007 | 13 | 0.130 |
Why?
|
Postoperative Complications | 2 | 2018 | 2301 | 0.130 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2015 | 11 | 0.130 |
Why?
|
Energy-Generating Resources | 1 | 2015 | 8 | 0.130 |
Why?
|
Antigens, Ly | 1 | 2015 | 53 | 0.130 |
Why?
|
Louisiana | 1 | 2015 | 26 | 0.130 |
Why?
|
RNA Splice Sites | 1 | 2015 | 39 | 0.130 |
Why?
|
Leg | 1 | 2017 | 249 | 0.130 |
Why?
|
Pulmonary Surfactant-Associated Protein C | 1 | 2015 | 44 | 0.130 |
Why?
|
Bacterial Load | 1 | 2015 | 69 | 0.130 |
Why?
|
Receptors, Nicotinic | 1 | 2017 | 309 | 0.130 |
Why?
|
Antiviral Agents | 1 | 2020 | 670 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 228 | 0.130 |
Why?
|
Pneumonectomy | 1 | 2016 | 123 | 0.130 |
Why?
|
Systole | 1 | 2015 | 178 | 0.130 |
Why?
|
Biomass | 1 | 2015 | 131 | 0.130 |
Why?
|
Colony Count, Microbial | 1 | 2014 | 124 | 0.120 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2014 | 52 | 0.120 |
Why?
|
Hypertension, Pulmonary | 1 | 2006 | 1900 | 0.120 |
Why?
|
Calcifediol | 1 | 2014 | 29 | 0.120 |
Why?
|
Transgenes | 1 | 2015 | 179 | 0.120 |
Why?
|
International Cooperation | 1 | 2015 | 182 | 0.120 |
Why?
|
Cytoplasm | 1 | 2015 | 276 | 0.120 |
Why?
|
Hepatorenal Syndrome | 1 | 2013 | 14 | 0.120 |
Why?
|
Tobacco Products | 1 | 2015 | 74 | 0.120 |
Why?
|
Phosphorylation | 3 | 2017 | 1733 | 0.120 |
Why?
|
Calcitriol | 1 | 2014 | 55 | 0.120 |
Why?
|
Quality of Life | 2 | 2021 | 2457 | 0.120 |
Why?
|
Weight Loss | 1 | 2018 | 663 | 0.120 |
Why?
|
Critical Illness | 1 | 2019 | 728 | 0.120 |
Why?
|
Esophageal and Gastric Varices | 1 | 2013 | 41 | 0.120 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 988 | 0.120 |
Why?
|
Acute Disease | 2 | 2015 | 984 | 0.120 |
Why?
|
Pleural Effusion | 1 | 2013 | 53 | 0.120 |
Why?
|
MAP Kinase Signaling System | 2 | 2008 | 304 | 0.120 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 86 | 0.120 |
Why?
|
Acanthamoeba | 1 | 2013 | 5 | 0.120 |
Why?
|
Fetal Hemoglobin | 1 | 2013 | 8 | 0.120 |
Why?
|
Partial Pressure | 1 | 2013 | 32 | 0.120 |
Why?
|
Hemoglobins, Abnormal | 1 | 2013 | 10 | 0.120 |
Why?
|
Oxyhemoglobins | 1 | 2013 | 19 | 0.120 |
Why?
|
Marfan Syndrome | 1 | 2013 | 43 | 0.110 |
Why?
|
Exercise | 2 | 2021 | 1743 | 0.110 |
Why?
|
Pulmonary Edema | 2 | 2004 | 141 | 0.110 |
Why?
|
Surface Properties | 1 | 2014 | 402 | 0.110 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 477 | 0.110 |
Why?
|
Colorado | 2 | 2021 | 4325 | 0.110 |
Why?
|
Thymectomy | 1 | 2012 | 15 | 0.110 |
Why?
|
Length of Stay | 1 | 2018 | 1077 | 0.110 |
Why?
|
Intracellular Space | 1 | 2013 | 72 | 0.110 |
Why?
|
Thymoma | 1 | 2012 | 31 | 0.110 |
Why?
|
Caspase Inhibitors | 1 | 2013 | 82 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 967 | 0.110 |
Why?
|
HIV Infections | 3 | 2018 | 2532 | 0.110 |
Why?
|
Cell Movement | 1 | 2017 | 929 | 0.110 |
Why?
|
Transfection | 1 | 2015 | 909 | 0.110 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 231 | 0.110 |
Why?
|
Water Supply | 1 | 2013 | 72 | 0.110 |
Why?
|
Sulfones | 1 | 2013 | 102 | 0.110 |
Why?
|
Neutrophil Activation | 1 | 2013 | 100 | 0.110 |
Why?
|
Water Microbiology | 1 | 2013 | 80 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2014 | 563 | 0.110 |
Why?
|
Nitriles | 1 | 2013 | 158 | 0.110 |
Why?
|
Adaptation, Physiological | 1 | 2016 | 510 | 0.110 |
Why?
|
Adenoviridae | 1 | 2013 | 195 | 0.110 |
Why?
|
Cystic Fibrosis | 1 | 2002 | 1003 | 0.110 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2012 | 74 | 0.110 |
Why?
|
Caspase 3 | 1 | 2013 | 246 | 0.110 |
Why?
|
Pandemics | 1 | 2020 | 1401 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 3 | 2015 | 312 | 0.100 |
Why?
|
Biodiversity | 1 | 2016 | 386 | 0.100 |
Why?
|
Lipid Metabolism | 1 | 2015 | 482 | 0.100 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2012 | 130 | 0.100 |
Why?
|
Anti-HIV Agents | 2 | 2018 | 685 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 290 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2013 | 228 | 0.100 |
Why?
|
Casein Kinase II | 2 | 2009 | 21 | 0.100 |
Why?
|
Bacterial Proteins | 3 | 2016 | 775 | 0.100 |
Why?
|
Drug Discovery | 1 | 2012 | 128 | 0.100 |
Why?
|
Phosphatidylglycerols | 1 | 2011 | 20 | 0.100 |
Why?
|
Amino Acid Sequence | 2 | 2013 | 2123 | 0.100 |
Why?
|
Oxidative Stress | 2 | 2010 | 1204 | 0.100 |
Why?
|
Blotting, Northern | 1 | 2010 | 199 | 0.100 |
Why?
|
Cerebrospinal Fluid Otorrhea | 1 | 2010 | 6 | 0.100 |
Why?
|
Facial Nerve Diseases | 1 | 2010 | 4 | 0.100 |
Why?
|
Liver Failure | 1 | 2011 | 94 | 0.100 |
Why?
|
Earache | 1 | 2010 | 5 | 0.100 |
Why?
|
Mastoiditis | 1 | 2010 | 7 | 0.100 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 36 | 0.100 |
Why?
|
Eicosanoids | 1 | 2011 | 55 | 0.100 |
Why?
|
RNA, Small Interfering | 2 | 2010 | 581 | 0.100 |
Why?
|
United States | 6 | 2022 | 13272 | 0.090 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2010 | 22 | 0.090 |
Why?
|
Time Factors | 4 | 2021 | 6682 | 0.090 |
Why?
|
Temporal Bone | 1 | 2010 | 44 | 0.090 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 188 | 0.090 |
Why?
|
Adolescent | 7 | 2018 | 18948 | 0.090 |
Why?
|
Liver Neoplasms | 1 | 2014 | 546 | 0.090 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 124 | 0.090 |
Why?
|
Multiple Myeloma | 1 | 2011 | 103 | 0.090 |
Why?
|
Linezolid | 2 | 2020 | 17 | 0.090 |
Why?
|
Purpura | 1 | 2009 | 13 | 0.090 |
Why?
|
Smoking Prevention | 1 | 2010 | 150 | 0.090 |
Why?
|
STAT6 Transcription Factor | 1 | 2009 | 24 | 0.090 |
Why?
|
In Vitro Techniques | 2 | 2020 | 1130 | 0.090 |
Why?
|
Databases, Factual | 1 | 2015 | 1287 | 0.090 |
Why?
|
Lymphocyte Antigen 96 | 1 | 2009 | 24 | 0.090 |
Why?
|
Arginase | 1 | 2009 | 30 | 0.090 |
Why?
|
Transcription, Genetic | 3 | 2016 | 1355 | 0.090 |
Why?
|
Bacteria | 1 | 2016 | 772 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2013 | 406 | 0.090 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2009 | 89 | 0.080 |
Why?
|
Transcriptional Activation | 1 | 2010 | 360 | 0.080 |
Why?
|
Spleen | 2 | 2008 | 543 | 0.080 |
Why?
|
Testicular Neoplasms | 1 | 2009 | 85 | 0.080 |
Why?
|
Gentian Violet | 1 | 2008 | 2 | 0.080 |
Why?
|
Tuberculosis, Meningeal | 1 | 2008 | 7 | 0.080 |
Why?
|
Phenazines | 1 | 2008 | 10 | 0.080 |
Why?
|
Breast Neoplasms | 1 | 2020 | 1994 | 0.080 |
Why?
|
HIV-1 | 1 | 2014 | 783 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2012 | 616 | 0.080 |
Why?
|
Genes, Bacterial | 1 | 2008 | 165 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2019 | 2784 | 0.080 |
Why?
|
Metalloporphyrins | 1 | 2008 | 109 | 0.080 |
Why?
|
Communicable Disease Control | 1 | 2008 | 74 | 0.080 |
Why?
|
Oxygen | 1 | 2013 | 887 | 0.080 |
Why?
|
Incidence | 1 | 2015 | 2527 | 0.080 |
Why?
|
Arginine | 1 | 2009 | 254 | 0.080 |
Why?
|
Mutation | 2 | 2017 | 3493 | 0.080 |
Why?
|
Global Health | 1 | 2010 | 352 | 0.080 |
Why?
|
Blood Pressure | 1 | 2015 | 1713 | 0.080 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 256 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2008 | 159 | 0.080 |
Why?
|
Hepatitis C, Chronic | 1 | 2009 | 150 | 0.080 |
Why?
|
Chemotaxis | 1 | 2008 | 141 | 0.080 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 167 | 0.080 |
Why?
|
Toll-Like Receptor 2 | 1 | 2008 | 131 | 0.080 |
Why?
|
Health Status | 2 | 2021 | 758 | 0.080 |
Why?
|
Biomarkers | 4 | 2021 | 3662 | 0.080 |
Why?
|
Tumor Burden | 2 | 2021 | 277 | 0.070 |
Why?
|
Estrogens | 1 | 2010 | 325 | 0.070 |
Why?
|
Pneumonia | 1 | 2012 | 605 | 0.070 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2020 | 547 | 0.070 |
Why?
|
Tricuspid Valve | 1 | 2006 | 26 | 0.070 |
Why?
|
Fibroma | 1 | 2006 | 20 | 0.070 |
Why?
|
Cell Transformation, Viral | 1 | 2006 | 22 | 0.070 |
Why?
|
Heart Neoplasms | 1 | 2006 | 51 | 0.070 |
Why?
|
Obesity | 1 | 2019 | 2786 | 0.070 |
Why?
|
Autoantibodies | 1 | 2013 | 1353 | 0.070 |
Why?
|
Child, Preschool | 5 | 2018 | 9755 | 0.070 |
Why?
|
Cell Line, Transformed | 1 | 2006 | 140 | 0.070 |
Why?
|
Granuloma, Respiratory Tract | 1 | 2005 | 12 | 0.070 |
Why?
|
Caspase 1 | 1 | 2006 | 143 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 884 | 0.070 |
Why?
|
Nutritional Status | 2 | 2018 | 306 | 0.070 |
Why?
|
Phenylalanine | 1 | 2006 | 69 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 1 | 2008 | 310 | 0.070 |
Why?
|
Kartagener Syndrome | 1 | 2005 | 25 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 1174 | 0.070 |
Why?
|
T-Lymphocyte Subsets | 1 | 2008 | 409 | 0.070 |
Why?
|
Lysosomes | 2 | 2021 | 136 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2006 | 299 | 0.070 |
Why?
|
Tryptophan | 1 | 2006 | 140 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2010 | 622 | 0.060 |
Why?
|
Fatty Acids | 1 | 2008 | 410 | 0.060 |
Why?
|
Radiography | 2 | 2004 | 888 | 0.060 |
Why?
|
Sex Characteristics | 1 | 2010 | 690 | 0.060 |
Why?
|
Tracheal Diseases | 1 | 2004 | 17 | 0.060 |
Why?
|
Esophageal Diseases | 1 | 2004 | 27 | 0.060 |
Why?
|
Lymphocytes | 2 | 2006 | 360 | 0.060 |
Why?
|
Prospective Studies | 2 | 2015 | 6704 | 0.060 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2007 | 535 | 0.060 |
Why?
|
Chemokines, CXC | 1 | 2004 | 66 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 766 | 0.060 |
Why?
|
Survival Rate | 1 | 2008 | 1810 | 0.060 |
Why?
|
Confidence Intervals | 2 | 2021 | 339 | 0.060 |
Why?
|
Signal Transduction | 2 | 2010 | 4902 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 292 | 0.060 |
Why?
|
Anthrax | 1 | 2003 | 9 | 0.060 |
Why?
|
Abnormalities, Multiple | 1 | 2005 | 183 | 0.060 |
Why?
|
Body Weight | 2 | 2019 | 958 | 0.060 |
Why?
|
Callitrichinae | 1 | 2023 | 1 | 0.060 |
Why?
|
Yersinia pestis | 1 | 2003 | 33 | 0.060 |
Why?
|
Callithrix | 1 | 2023 | 9 | 0.060 |
Why?
|
5' Flanking Region | 1 | 2003 | 8 | 0.060 |
Why?
|
NF-KappaB Inhibitor alpha | 1 | 2003 | 52 | 0.060 |
Why?
|
Data Accuracy | 1 | 2023 | 61 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2009 | 618 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2010 | 2328 | 0.060 |
Why?
|
Color | 1 | 2003 | 82 | 0.060 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2003 | 77 | 0.060 |
Why?
|
Respiratory Function Tests | 1 | 2004 | 563 | 0.060 |
Why?
|
I-kappa B Proteins | 1 | 2003 | 81 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 4734 | 0.050 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2002 | 26 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2010 | 1805 | 0.050 |
Why?
|
Gastroesophageal Reflux | 2 | 2020 | 252 | 0.050 |
Why?
|
Chromosome Mapping | 1 | 2023 | 518 | 0.050 |
Why?
|
Microtubule-Associated Proteins | 1 | 2003 | 187 | 0.050 |
Why?
|
Oxides | 1 | 2022 | 43 | 0.050 |
Why?
|
Airway Obstruction | 1 | 2004 | 182 | 0.050 |
Why?
|
Vascular Diseases | 1 | 2004 | 251 | 0.050 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2002 | 198 | 0.050 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 19 | 0.050 |
Why?
|
Epithelium | 1 | 2002 | 309 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 1265 | 0.050 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2021 | 46 | 0.050 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.050 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 70 | 0.050 |
Why?
|
Autophagy-Related Proteins | 1 | 2021 | 48 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2021 | 127 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2003 | 592 | 0.050 |
Why?
|
Child | 5 | 2018 | 19561 | 0.050 |
Why?
|
Sulfuric Acids | 1 | 2020 | 16 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2003 | 432 | 0.050 |
Why?
|
Biological Assay | 1 | 2021 | 123 | 0.050 |
Why?
|
Iron | 1 | 2022 | 239 | 0.050 |
Why?
|
Rifampin | 1 | 2020 | 71 | 0.050 |
Why?
|
Recurrence | 2 | 2018 | 998 | 0.050 |
Why?
|
Superoxides | 2 | 2013 | 225 | 0.050 |
Why?
|
Survival Analysis | 1 | 2004 | 1325 | 0.050 |
Why?
|
Respiratory Aspiration | 1 | 2020 | 36 | 0.050 |
Why?
|
Intensive Care Units | 2 | 2021 | 664 | 0.050 |
Why?
|
China | 1 | 2020 | 223 | 0.050 |
Why?
|
Transcription Factors | 1 | 2008 | 1616 | 0.050 |
Why?
|
Pulmonary Artery | 1 | 2006 | 1097 | 0.050 |
Why?
|
Primary Cell Culture | 1 | 2020 | 156 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2004 | 1531 | 0.050 |
Why?
|
Australia | 1 | 2020 | 223 | 0.040 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 1 | 2019 | 9 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2021 | 242 | 0.040 |
Why?
|
Retinal Dehydrogenase | 1 | 2019 | 40 | 0.040 |
Why?
|
Bacillus | 1 | 2019 | 15 | 0.040 |
Why?
|
Biomarkers, Tumor | 1 | 2005 | 1076 | 0.040 |
Why?
|
Culture Media, Conditioned | 1 | 2019 | 114 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2019 | 70 | 0.040 |
Why?
|
Topography, Medical | 1 | 2018 | 11 | 0.040 |
Why?
|
Cell Wall | 1 | 2019 | 53 | 0.040 |
Why?
|
Kanamycin | 1 | 2018 | 9 | 0.040 |
Why?
|
Capreomycin | 1 | 2018 | 2 | 0.040 |
Why?
|
Diarylquinolines | 1 | 2018 | 7 | 0.040 |
Why?
|
ROC Curve | 1 | 2020 | 494 | 0.040 |
Why?
|
Carbapenems | 1 | 2018 | 17 | 0.040 |
Why?
|
Levofloxacin | 1 | 2018 | 22 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 3264 | 0.040 |
Why?
|
Child Nutrition Disorders | 1 | 2018 | 17 | 0.040 |
Why?
|
Clofazimine | 1 | 2018 | 15 | 0.040 |
Why?
|
Hyperinsulinism | 1 | 2019 | 109 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2018 | 32 | 0.040 |
Why?
|
Health Services | 1 | 2019 | 110 | 0.040 |
Why?
|
Early Ambulation | 1 | 2018 | 15 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2004 | 668 | 0.040 |
Why?
|
Proteomics | 1 | 2004 | 890 | 0.040 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 457 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2021 | 384 | 0.040 |
Why?
|
Health Resources | 1 | 2019 | 136 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2004 | 936 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 1184 | 0.040 |
Why?
|
Europe | 1 | 2018 | 369 | 0.040 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2018 | 99 | 0.040 |
Why?
|
Malnutrition | 1 | 2018 | 69 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2021 | 1234 | 0.040 |
Why?
|
Health Expenditures | 1 | 2019 | 202 | 0.040 |
Why?
|
Nitrosation | 1 | 2017 | 10 | 0.040 |
Why?
|
Interleukin-1 | 1 | 2002 | 987 | 0.040 |
Why?
|
Enterocytes | 1 | 2017 | 15 | 0.040 |
Why?
|
Family Characteristics | 1 | 2018 | 164 | 0.040 |
Why?
|
Coinfection | 1 | 2018 | 122 | 0.040 |
Why?
|
Sepsis | 1 | 2003 | 546 | 0.040 |
Why?
|
Immunity, Cellular | 1 | 2019 | 276 | 0.040 |
Why?
|
Gambia | 1 | 2016 | 12 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2017 | 52 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2011 | 119 | 0.040 |
Why?
|
Self Report | 1 | 2021 | 730 | 0.040 |
Why?
|
Age of Onset | 1 | 2018 | 479 | 0.040 |
Why?
|
Two-Hybrid System Techniques | 2 | 2009 | 58 | 0.040 |
Why?
|
Regulon | 1 | 2016 | 32 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 1158 | 0.040 |
Why?
|
Uganda | 1 | 2016 | 76 | 0.040 |
Why?
|
Nitrogen Oxides | 1 | 2016 | 55 | 0.040 |
Why?
|
Models, Animal | 1 | 2018 | 373 | 0.040 |
Why?
|
Baths | 1 | 2016 | 20 | 0.030 |
Why?
|
Humidity | 1 | 2016 | 45 | 0.030 |
Why?
|
Syndrome | 1 | 2017 | 363 | 0.030 |
Why?
|
Family Health | 1 | 2017 | 201 | 0.030 |
Why?
|
Mental Disorders | 1 | 2004 | 952 | 0.030 |
Why?
|
Program Development | 1 | 2018 | 372 | 0.030 |
Why?
|
Pedigree | 1 | 2017 | 492 | 0.030 |
Why?
|
Housing | 1 | 2016 | 125 | 0.030 |
Why?
|
Infant | 3 | 2007 | 8523 | 0.030 |
Why?
|
Mental Health | 1 | 2021 | 571 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2018 | 312 | 0.030 |
Why?
|
Metabolic Syndrome | 1 | 2019 | 395 | 0.030 |
Why?
|
Science | 1 | 2016 | 53 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 687 | 0.030 |
Why?
|
Ethiodized Oil | 1 | 2014 | 6 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2017 | 302 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2019 | 560 | 0.030 |
Why?
|
Hepatic Artery | 1 | 2014 | 56 | 0.030 |
Why?
|
Dyneins | 2 | 2005 | 30 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2021 | 2737 | 0.030 |
Why?
|
Colitis | 1 | 2017 | 227 | 0.030 |
Why?
|
Smoking Cessation | 1 | 2018 | 363 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 163 | 0.030 |
Why?
|
Protein Kinases | 1 | 2016 | 325 | 0.030 |
Why?
|
Recovery of Function | 1 | 2018 | 610 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2018 | 632 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 2904 | 0.030 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2014 | 86 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 731 | 0.030 |
Why?
|
Hartmannella | 1 | 2013 | 2 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1860 | 0.030 |
Why?
|
Clinical Competence | 1 | 2020 | 973 | 0.030 |
Why?
|
Doxorubicin | 1 | 2014 | 304 | 0.030 |
Why?
|
Rituximab | 1 | 2013 | 161 | 0.030 |
Why?
|
Water | 1 | 2016 | 433 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2013 | 213 | 0.030 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2011 | 54 | 0.020 |
Why?
|
Lipopeptides | 1 | 2011 | 16 | 0.020 |
Why?
|
Plasma Cells | 1 | 2011 | 60 | 0.020 |
Why?
|
Odds Ratio | 1 | 2014 | 1043 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 1519 | 0.020 |
Why?
|
Group IV Phospholipases A2 | 1 | 2011 | 45 | 0.020 |
Why?
|
Students | 1 | 2016 | 529 | 0.020 |
Why?
|
Glutathione Peroxidase | 1 | 2010 | 53 | 0.020 |
Why?
|
Catalase | 1 | 2010 | 125 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2010 | 90 | 0.020 |
Why?
|
Liver | 2 | 2011 | 1827 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 172 | 0.020 |
Why?
|
Toll-Like Receptors | 1 | 2011 | 169 | 0.020 |
Why?
|
Lipoproteins | 1 | 2011 | 164 | 0.020 |
Why?
|
Spirometry | 1 | 2010 | 291 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2010 | 187 | 0.020 |
Why?
|
Cysteine | 1 | 2011 | 187 | 0.020 |
Why?
|
U937 Cells | 1 | 2009 | 30 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 1922 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2010 | 150 | 0.020 |
Why?
|
Biomedical Research | 1 | 2016 | 630 | 0.020 |
Why?
|
Spermatids | 1 | 2009 | 18 | 0.020 |
Why?
|
Blood Cells | 1 | 2009 | 39 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 294 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 2009 | 70 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2003 | 2933 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 2010 | 345 | 0.020 |
Why?
|
Environment | 1 | 2010 | 357 | 0.020 |
Why?
|
Fimbriae, Bacterial | 1 | 2008 | 28 | 0.020 |
Why?
|
Hospitals | 1 | 2013 | 633 | 0.020 |
Why?
|
Down-Regulation | 1 | 2010 | 654 | 0.020 |
Why?
|
Ecosystem | 1 | 2013 | 579 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2011 | 1128 | 0.020 |
Why?
|
Biopsy | 1 | 2011 | 1090 | 0.020 |
Why?
|
Saskatchewan | 1 | 2007 | 7 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2010 | 931 | 0.020 |
Why?
|
X-Rays | 1 | 2007 | 28 | 0.020 |
Why?
|
Nucleocapsid Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
DNA, Ribosomal | 1 | 2007 | 82 | 0.020 |
Why?
|
Phagocytosis | 1 | 2008 | 368 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2007 | 147 | 0.020 |
Why?
|
Molecular Structure | 1 | 2008 | 463 | 0.020 |
Why?
|
Toll-Like Receptor 4 | 1 | 2009 | 335 | 0.020 |
Why?
|
Echocardiography, Transesophageal | 1 | 2006 | 92 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 1625 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 1981 | 0.020 |
Why?
|
Axonemal Dyneins | 1 | 2005 | 8 | 0.020 |
Why?
|
Mice, Obese | 1 | 2005 | 59 | 0.020 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2008 | 291 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 783 | 0.020 |
Why?
|
HSP40 Heat-Shock Proteins | 1 | 2005 | 22 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2007 | 324 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2006 | 347 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 2005 | 97 | 0.020 |
Why?
|
Heat-Shock Proteins | 1 | 2005 | 129 | 0.020 |
Why?
|
Health Services Administration | 1 | 2004 | 9 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2005 | 328 | 0.020 |
Why?
|
Extravascular Lung Water | 1 | 2004 | 11 | 0.020 |
Why?
|
Nitrites | 1 | 2004 | 81 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 108 | 0.020 |
Why?
|
Viral Fusion Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
t-Complex Genome Region | 1 | 2003 | 3 | 0.010 |
Why?
|
Testicular Hormones | 1 | 2003 | 9 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2009 | 2501 | 0.010 |
Why?
|
Ascorbic Acid | 1 | 2004 | 116 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2007 | 1318 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2007 | 551 | 0.010 |
Why?
|
Demography | 1 | 2004 | 290 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 1990 | 0.010 |
Why?
|
Deglutition Disorders | 1 | 2004 | 135 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2003 | 324 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2003 | 343 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2003 | 339 | 0.010 |
Why?
|
Probability | 1 | 2003 | 316 | 0.010 |
Why?
|
Glutathione | 1 | 2004 | 327 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 416 | 0.010 |
Why?
|
Canada | 1 | 2003 | 355 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2003 | 154 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2002 | 44 | 0.010 |
Why?
|
Enzyme Induction | 1 | 2002 | 94 | 0.010 |
Why?
|
Indomethacin | 1 | 2002 | 76 | 0.010 |
Why?
|
Reference Values | 1 | 2003 | 789 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2002 | 72 | 0.010 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2002 | 67 | 0.010 |
Why?
|
Blood Proteins | 1 | 2004 | 249 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 156 | 0.010 |
Why?
|
Dinoprostone | 1 | 2002 | 193 | 0.010 |
Why?
|
Injury Severity Score | 1 | 2003 | 541 | 0.010 |
Why?
|
Ultrasonography | 1 | 2005 | 740 | 0.010 |
Why?
|
Uric Acid | 1 | 2004 | 354 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2002 | 282 | 0.010 |
Why?
|
Imidazoles | 1 | 2002 | 234 | 0.010 |
Why?
|
Rats | 1 | 2009 | 5426 | 0.010 |
Why?
|
United States Department of Veterans Affairs | 1 | 2004 | 564 | 0.010 |
Why?
|
Proteome | 1 | 2004 | 357 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 788 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2002 | 433 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 2186 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2003 | 1855 | 0.010 |
Why?
|
Pyridines | 1 | 2002 | 440 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2002 | 646 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 836 | 0.010 |
Why?
|
Proteins | 1 | 2004 | 953 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2002 | 702 | 0.010 |
Why?
|
Young Adult | 1 | 2010 | 11094 | 0.010 |
Why?
|
Veterans | 1 | 2004 | 1203 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2004 | 4882 | 0.010 |
Why?
|